A Phase 2, Randomized, Observer-Blind, Controlled, Age De-escalation, Dosage Escalation Study to Assess the Safety and Immunogenicity of a Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine in Healthy Young Children, Infants, and Neonates in Panama
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Poliovirus vaccine (Primary)
- Indications Poliomyelitis
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 27 Feb 2024 Planned End Date changed from 28 Aug 2025 to 20 Nov 2025.
- 27 Feb 2024 Planned primary completion date changed from 28 Aug 2025 to 20 Nov 2025.
- 01 Dec 2023 Status changed from not yet recruiting to recruiting.